Background: Diffuse intrinsic pontine gliomas (DIPGs) have a dismal prognosis. Previously, diagnosis was based on a typical clinical presentation and magnetic resonance imaging findings. After the start of the era of biopsies, DIPGs bearing H3 K27 mutations have been reclassified into a novel entity, diffuse midline glioma, based on the presence of this molecular alteration. However, it is not well established how clinically diagnosed DIPG overlap with H3 K27-mutated diffuse midline gliomas, and whether rare long-term survivors also belong to this group.
INTRODUCTION
Diffuse intrinsic pontine gliomas (DIPGs) are rare and highly malignant tumors that typically arise in children and adolescents. They have a notorious prognosis, with most patients deceasing within a year from diagnosis 1 and less than 10% surviving beyond 24 months. 2 Surgery is precluded, irradiation alleviates the symptoms only transiently, and chemotherapies lack any significant effect on the outcome. 1 DIPG diagnosis has traditionally been made on clinical grounds based on characteristic symptoms and magnetic resonance imaging (MRI) findings.
Abbreviations: DIPG, diffuse intrinsic pontine glioma; IHC, immunohistochemistry; MRI, magnetic resonance imaging; MVD, microvessel density; NGS, next-generation sequencing; OS, overall survival; PCR, polymerase chain reaction; WHO, World Health Organization Recent molecular studies have revealed that most malignant gliomas arising in the midline structures of the central nervous system-brainstem, thalamus, and spinal cord-harbor a highly specific point mutation, K27M, in histone 3.3, 3.2, or 3.1. [3] [4] [5] [6] [7] The dismal prognosis specifically concerns those tumors bearing H3 K27 mutations. 2 In the revised 2016 edition of the World Health Organization (WHO) brain tumor classification, these neoplasms constitute a new entity termed as diffuse midline glioma, H3 K27M-mutant. 8 H3 K27M-mutated DIPGs are now included in this category. However, a subset of brainstem gliomas lack K27M mutations and thus cannot be classified as any established glioma subtype. More data are needed to understand the clinical picture and underlying biology of these tumors.
In this study, biopsy and autopsy samples from previously diagnosed DIPG tumors were analyzed using next-generation sequencing (NGS) and immunohistochemistry (IHC). Our aims were as follows: (i) reclassify these tumors according to the WHO 2016 brain tumor classification and explore the correlation between clinical DIPG diagnosis and molecular diagnosis; (ii) screen the tumors for both known and as yet unstudied genetic alterations as well as pathological protein expression; (iii) explore tumor specimens of long-term survivors to find specific factors that can explain the unanticipated disease course; and (iv) develop an NGS panel applicable for diagnostic, therapeutic, and prognostic purposes for various pediatric brain neoplasms.
METHODS

Patients and samples
Diagnoses were made and the patients recruited to the study before the Ethics Committee approved the study design, and informed consent was received from patients still alive at the end of the follow-up.
Next-generation sequencing
Tumor samples were analyzed with NGS utilizing a custom-made AmpliSeq panel, designed using AmpliSeq Designer pipeline Version 4.4.2 (Table 1, Supplementary Tables S1 and S2 For p53, nuclear expression in >10% of tumor cells were considered positive and predictive for TP53 mutation. 9 cMYC and EGFR expressions were graded on a four-step scale (0 = 0%; 1 = 1-25%; 2 = 26-50%; 3 = >50%). Further, the staining intensity of H3 K27M was evaluated as either high or low. 
Immunohistochemistry
Microvessel density
Statistical considerations
The statistical analysis was conducted using IBM SPSS Statistics, Version 22 (SPSS, Chicago, IL, USA) and utilizing Kaplan-Meier survival analysis and Mann-Whitney U test. Overall survival (OS) was defined as the period from diagnosis to death or the end of follow-up. In analyzing the relationship between MVD and survival, patients were dichotomized into two groups according to the median MVD. P-values <0.05 were considered significant.
RESULTS
Patient demographics
This study comprised 26 tumor samples, including 18 biopsies and 8 autopsy specimens, obtained from 23 patients (Table 2 and   Supplementary Table S3 
Alterations in H3 K27
The most frequently discovered mutation in our study was H3 K27M, found in 20 of 23 patients (87%) when including both NGS and IHC Table 3) . Samples of 20 patients were analyzed by NGS and the H3.3 K27M mutation was found in 18 patients (90%), whereas no H3.1 K27M mutation was encountered. IHC revealed H3 K27M expression in 18 of 21 patients (86%) ( Fig. 2A ) with high staining intensity in 13 patients (72%) and low intensity in five patients (28%). Four of five samples with low K27M staining intensity were autopsy specimens. We did not find a clear correlation between H3 K27 status and survival in our small cohort.
Alterations in TP53
TP53 was the second most commonly altered gene in our cohort and was found in 10 patients (50%) by NGS. Using IHC, 14 of 21 patients (67%) expressed p53 in >10% of the tumor cells. One of our patients did not express p53 by IHC although NGS analysis discovered a TP53 mutation (Fig. 2B) , whereas four samples showed strong IHC positivity for p53, but lacked TP53 mutations in the NGS analysis (Fig. 2C ).
Other molecular alterations
EGFR was mutated in one patient (5%) by NGS. This patient lacked protein expression by IHC. Using IHC, EGFR expression was evident in six patients (29%). None of these patients had EGFR mutations in NGS.
Three patients (15%) had MET mutations, two patients (10%) had mutations in PDGFRA, and one patient (5%) a PDGFRA amplification. Additionally, two patients (10%) had mutations in SMARCA4, one patient (5%) had a mutation in PPAR , and one patient (5%) a mutation in PTEN. VEGFR was mutated and amplified in one patient (5%) each.
One of the long-term survivors with an OS of 7.5 years at the end of follow-up harbored an IDH1 mutation (R132S) in the diagnostic biopsy.
Only NGS discovered the mutation, since the antibody utilized in IHC only recognizes the most common IDH1 alteration, which is R132H.
In addition, IHC revealed cMYC expression in 15 of 21 (71%) patients (Fig. 2D) . All positive specimens were biopsies. None of the autopsy samples expressed cMYC by IHC. We had three matched, biopsy-autopsy pairs from the same patients, and all biopsies were positive for cMYC, while the autopsy pairs were negative. We did not find mutations or amplifications in cMYC by NGS. 
Microvessel density
MVD showed a wide variation in both biopsies and autopsy samples. K27M-mutant. 8 These tumors are associated with the most aggressive disease and the most dismal prognosis. 2 In earlier DIPG studies, the K27M mutation has resided in histone 3.3 in 48-71% of the cases, 2-7,17 whereas H3.1-K27M mutations occur at a frequency of 11-25%. [2] [3] [4] [5] 17 In our cohort, 87% of the patients diagnosed with a DIPG based on clinical findings also harbored a H3 K27 mutation. Thus, in our cohort, brainstem tumors with symptoms and a radiological presentation characteristic for DIPG most often belonged to a molecular entity of H3 K27-mutated diffuse midline gliomas, showing that careful clinical DIPG diagnosis usually correlates with a molecular diagnosis of aggressive H3 K27M-mutated gliomas.
Our study cohort included three patients (13%) with wild-type H3 K27. The OS in this group did not statistically differ significantly from The reason for this fast tumor progression is equivocal. The fact that no radiation therapy was given to this patient may also have influenced the disease course. Nonetheless, there may be other, yet unknown, genetic factors that affect the outcomes of patients without H3 K27
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mutations.
The other patients who were negative for H3 K27M mutations were two long-term survivors who were alive at the end of follow-up, 4.0 and 7.5 years from diagnosis, respectively. Both were initially diagnosed to have DIPG at their baseline according to radiological and histological findings. However, current analyses discovered features that warranted a reevaluation of these diagnoses.
In the first patient, the initial radiological diagnosis was DIPG.
The patient was included in this study according to the initial diagnosis. However, when reevaluated for this study, the MRI images of this patient showed distinctive features compared to other DIPGs (Supplementary Figs. S1-S3): the lesion has diffuse boundary to the normal tissue, but it is smaller and the mass effect is slighter than in other patients. Histology of the biopsied lesion was consistent with grade II astrocytoma infiltration zone. Unfortunately, NGS was impossible to conduct due to the low tumor cell content of the tumor sample (<10%), and we were thus not able to confirm the molecular diagnosis of this particular tumor. This patient received treatment according to the antiangiogenic Angiocomb protocol. 10 After radiotherapy with concomitant topotecan infusions, the tumor disappeared radiologically, and follow-up MRIs confirmed a sustained complete response. 10 When taking into account the radiological reassessment and the lack of molecular findings, it now seems unlikely that this patient had a real DIPG. Consequently, combined radiological, histological, and molecular diagnosis is essential to confirm the clinical diagnosis and would have been of highest importance in this case. This is the main message of our study.
The other long-term survivor had a typical MRI appearance of the tumor at diagnosis (Supplementary Figs. S4-S9 ). However, current molecular findings in the biopsy indicate that this tumor was not a classic aggressive DIPG. An IDH1 mutation was discovered by NGS in the biopsy. IHC was unable to detect this alteration, as the antibody only recognizes the most common mutation, R132H. 18 The R132S mutation found in our patient has prevalence of only 1.4% in all IDH1/2-mutated gliomas. 18 In the revised WHO 2016 tumor classification, the IDH mutation status divides diffuse gliomas into further subgroups. 8 Mutations in IDH1 or IDH2 occur in approximately 10%
of glioblastomas, 8 predominately among adolescents and in cortical tumors. 19 IDH1 mutations confer a favorable prognostic marker that is associated with extended survival in supratentorial gliomas, 18,20 but these have thus far been regarded as being absent in pediatric brainstem astrocytomas. 2, 4, 6, 7, 21, 22 The IDH1 mutation found in our second long-term survivor now warrants a reevaluation of this paradigm.
Furthermore, this finding also indicates that a molecular diagnosis of a biopsy is needed to confirm the real nature of a brainstem tumor despite its typical clinical and radiological presentation.
By NGS, TP53 mutations were found in 10 patients (50%), a prevalence similar to those reported in most earlier studies on DIPGs. 6, 7, 23 There was some discrepancy between the NGS and the IHC results.
One patient was negative for p53 by IHC, although NGS did discover a TP53 mutation. This result is not unforeseen, since NGS is superior to IHC in both sensitivity and specificity, and truncating TP53 mutations are not recognized by IHC. 9 Four samples showed strong IHC positivity for p53, but lacked TP53 mutations in an NGS analysis. Pollack et al. 24 proposed that TP53 overexpression without gene mutation can occur as a stress-related response to anoxia and DNA damage. Moreover, we cannot exclude the fact that the old age of some samples may have yielded false-negative TP53 mutation status. The rather high degree of inconsistency in the NGS and IHC results was evident despite the utilization of a 10% cutoff for positive and negative IHC results, a criterion that is considered superior to previous classifications. 9 Thus, although IHC is the standard method for screening TP53 mutations in many laboratories, a parallel genetic approach would be preferable.
The tyrosine kinase receptors PDGFRA, EGFR, and VEGFR as well as the mTOR pathway have been suggested as potential targets for novel treatments of brainstem gliomas. The presence of these targets in diagnostic biopsies would, therefore, be of great interest. In previous studies, PDGFRA amplification/gain or mutations have been encountered quite frequently in DIPG. 2, 6, 14, 23, [25] [26] [27] [28] In our cohort, two patients had mutations in PDGFRA, and one patient a PDGFRA amplification. EGFR amplifications and mutations, common in adult glioblastomas, 29 are rare in DIPGs. 2, 26, 28 Interestingly, we found an EGFR mutation in one of our DIPG patients who also had a H3 K27M mutation. This tumor lacked EGFR expression by IHC, which may reflect the incapability of the antibody to recognize the mutated form of EGFR. EGFR expression was found in six patients, but none of these harbored EGFR mutations or amplifications.
Consistent with our study, other studies have also reported a lack of association between EGFR gene alterations and protein expression. 2, 28 Regarding the mTOR pathway, MET 30 and PTEN 7 mutations have been reported to occur only sporadically in DIPGs. Alterations in VEGFR are rare. However, in our cohort, VEGFR was mutated and amplified in one patient each. In all, our results are largely consistent with earlier studies, but the proportion of rare EGFR and VEGFR alterations were higher than previously reported.
Two patients harbored SMARCA4 mutations. SMARCA4 encodes a component of the chromatin remodeling complex SWI/SNF, and mutations in this gene distinguish a minority of atypical teratoid/rhabdoid tumors (AT/RTs). 31 In addition, one patient had a mutation in PPAR , a multifunctional nuclear receptor involved in insulin and glucose metabolism, inflammatory processes, and immune responses. 32 There is preliminary evidence of its role in adult gliomagenesis, and PPAR protein expression levels have been reported to correlate inversely with the histological grade. 32 Further, PPAR agonists have demonstrated antitumor and antiangiogenic effects in preclinical studies. 32 The functional impact of SMARCA4 and PPAR mutations in diffuse brainstem gliomas, however, remains unclear.
Amplification of the oncogene cMYC is associated with an inferior prognosis in other tumors, such as medulloblastomas. 33 The correlation of cMYC amplification to prognosis in DIPG is yet not established. In our study, none of the tumors had cMYC amplification, but protein expression was evident in 15 patients (71%), excluding the long-term survivors. It is known that cMYC can be overexpressed also without gene amplification, such as through translocations. [34] [35] [36] Interestingly, cMYC overexpression was found exclusively in the biopsy samples. This finding also applies to the three matched biopsy-autopsy pairs in this study; biopsies were positive for cMYC expression while autopsy samples from the same patients were negative. Technical issues related to tissue preservation at autopsy may have interfered with the results, but the high degree of cMYC positivity in the biopsies and the lack of expression in the autopsy samples may also indicate that some factor-potentially radiotherapy, which most of the patients received-could have eradicated the cMYC-positive tumor cells while leaving treatment-resistant subclones remaining. cMYC expression did not correlate with survival in our cohort, but it would be interesting to validate the significance in a larger patient group.
Angiogenesis-related pathways have been proposed to be crucial in a subset of DIPGs. 3, 37 How differences in angiogenesis signaling are reflected on the histological level is still unknown, causing us to study the MVD in our tumor samples. Due to the scarce size of the biopsies, we had to utilize different methods to evaluate the MVD in the biopsies and autopsy samples. The MVD showed a wide variation in both biopsies and autopsy samples, but it did not correlate with survival or with the utilization of metronomic therapy.
There are certain caveats associated with our study. Substantial tumor heterogeneity for certain genetic alterations 26, 30 increases the risk of sampling bias. Due to the small number of samples, we were unable to conduct more genetic analyses or find any statistically significant correlations to survival.
In conclusion, molecular analysis of brainstem gliomas previously diagnosed as DIPGs revealed H3 K27M mutations in most of the cases.
DIPGs with a typical MRI appearance most often corresponded to diffuse midline glioma, H3 K27-mutant. However, three patients (13%)
did not fit into this category. One of these patients was a long-term survivor who harbored an IDH1 mutation, a novel finding in pediatric brainstem gliomas, which implies that this tumor was not a classic DIPG. Thus, clinical and radiological diagnosis is not always sufficient to categorize brainstem tumors. Nowadays more and more subjects undergo a biopsy, and the combined histological and molecular findings should be taken into consideration when making the final diagnosis.
